



**RAPPORT
SUR L'EXERCICE DES
DROITS DE VOTE
EXERCICE 2023
AESCULAPE SRI**

58 avenue Marceau, 75008 Paris
T. +33 (0)1 45 05 55 55
www.montpensier.com

1. Préambule

Montpensier Finance met en œuvre des process et une organisation ayant comme objectif de respecter les Principes pour l'Investissement Responsable édictés par les Nations Unies.

Les Principes pour l'Investissement Responsable des Nations Unies déterminent un cadre international référent et reconnu pour les acteurs de la finance.

En signant ces principes, Montpensier Finance s'engage publiquement, en tant qu'investisseur, à les adopter et à les appliquer dans la mesure où cela est compatible avec ses responsabilités de gestionnaire. Montpensier Finance s'engage également à évaluer l'efficacité et à améliorer le contenu des Principes avec le temps. Nous sommes convaincus que cela nous rendra plus à même de répondre à nos engagements envers les bénéficiaires et de mieux faire concorder nos activités d'investissement avec l'intérêt général.

Dans ce cadre, Montpensier Finance a mis en place une Politique d'engagement actionnarial, qui se compose d'une Politique de Vote, qui s'applique à la gestion active actions ; et d'une Politique d'Engagement, qui s'applique à la gestion active actions et obligations convertibles.

1.1. Politique de Vote

L'exercice du droit de vote est un élément important du dialogue avec les émetteurs.

Montpensier Finance considère l'exercice du droit de vote comme faisant intégralement partie de sa gestion et comme devant être exercé dans le meilleur intérêt des porteurs.

La politique de vote mise en place par Montpensier Finance est résumée ci-après.

➤ Principes généraux

La politique de droits de vote de Montpensier Finance vise à promouvoir la valorisation à long terme des investissements des OPC. Elle encourage la diffusion des meilleures pratiques de gouvernance et de déontologie professionnelle.

Dans le cadre de la mise en œuvre des Principes de l'Investissement Responsable, il est recommandé aux gérants de voter au plus grand nombre d'Assemblées pour lesquelles ils estiment disposer des éléments d'information nécessaires afin de participer au vote, sous réserve d'impossibilités techniques les empêchant de participer au vote.

➤ L'organisation de l'exercice des droits de vote

Pour exercer les droits de vote attachés aux titres détenus par les OPC, les gérants s'appuient sur les principes énoncés dans les recommandations publiées par ISS Governance, dans sa politique Sustainability.

Montpensier Finance a souscrit à un abonnement ISS Proxy Research Services, qui fournit une recherche et des recommandations de vote, fondées sur une analyse approfondie, indépendante et objective des résolutions proposées au vote des actionnaires. Les publications ISS Governance sont encadrées par la politique de prévention des risques de conflits d'intérêt mise en place par ISS Governance.

Le périmètre ISS couvre l'ensemble des sociétés figurant dans les portefeuilles des OPC gérés par Montpensier Finance.

➤ Les principes de la politique de vote

Conformément à la déontologie, les gérants exercent leurs fonctions en toute indépendance, notamment vis-à-vis des émetteurs, et dans l'intérêt exclusif des porteurs.

Les gérants sont tout particulièrement sensibles aux résolutions qui seraient susceptibles de porter atteinte aux intérêts des actionnaires.

➤ Les conflits d'intérêts

Les gérants voteront dans l'intérêt des porteurs.

Si les gérants décèlent un conflit d'intérêts potentiel, ils doivent préalablement à leur vote consulter le RCCI de façon à garantir la primauté des intérêts des porteurs de parts des OPC.

La politique de vote complète est disponible sur le site internet de Montpensier Finance, rubrique Politique d'Engagement actionnarial - Politique de Vote :

- <https://www.montpensier.com/fr-FR/informations-reglementaires>

Le dernier rapport sur l'exercice des droits de vote est disponible sur notre site internet :

- https://www.montpensier.com/sites/default/files/public/documents/exercice-droits-de-vote_rapport.pdf

Le dernier rapport annuel sur l'exercice des droits de vote de chaque fonds actions labellisé, est accessible sur la page dédiée du fonds sur le site internet de Montpensier Finance.

1.2. Politique d'Engagement

➤ Principes généraux

La politique de vote mise en place par Montpensier Finance est complétée par une Politique d'Engagement.

L'univers des sociétés sur lesquelles les gérants sont invités à concentrer leur démarche d'engagement est constitué des sociétés qui ont une notation ESG jugée insuffisante, ou susceptibles d'être exposées à des controverses ESG, afin de les encourager à améliorer leurs pratiques sur les questions environnementales, sociales, et de gouvernance d'entreprise, qui sont des facteurs de performances durables.

➤ Démarche d'Engagement

Les équipes de gestion sont invitées à soulever toute question ou sujet d'attention auprès des entreprises lors de leurs échanges, en particulier lorsque les questions ESG apparaissent insuffisamment prises en compte ou communiquées.

Les gérants, assistés par l'analyste ISR, mèneront un dialogue positif et constructif de moyen - long terme avec les sociétés en portefeuille.

Ce dialogue peut prendre plusieurs formes :

- ✓ Contacts avec la société ;
- ✓ Envoi des intentions de vote des gérants à la société, préalablement à la tenue de l'Assemblée Générale.

Cet engagement a comme objectif :

- ✓ D'encourager les sociétés à mettre en œuvre une démarche ESG ;
- ✓ D'encourager les sociétés à communiquer sur leurs pratiques ESG.

➤ Mise en oeuvre

En complément des initiatives d'engagement que nous conduisons en direct, habituellement auprès de Petites et Moyennes Valeurs, nous participons aux actions collectives d'engagement en « pool », mises en œuvre par ISS dans le cadre de son programme ISS Ethix, pour les Grandes Valeurs.

La démarche de Montpensier Finance s'appuie sur :

- ✓ La recherche ESG de MSCI ESG Research, pour déterminer la notation ESG des valeurs ;
- ✓ L'analyse des équipes de gestion ;
- ✓ Les recommandations sur la gouvernance d'entreprise publiées par ISS Governance, dans le cadre de l'application de la Politique de Vote de Montpensier Finance ;
- ✓ Les actions collectives d'engagement mises en œuvre par ISS dans le cadre de son programme ISS Ethix.

La démarche mise en œuvre s'applique de différentes manières :

- ✓ Exercer nos droits de vote en prenant en compte les critères ESG ;
- ✓ Encourager et accompagner les sociétés dans une démarche ESG plus forte.

La politique d'engagement est disponible sur le site internet de Montpensier Finance, rubrique Politique d'Engagement actionnarial - Politique d'Engagement :

- <https://www.montpensier.com/fr-FR/informations-reglementaires>

Le dernier rapport sur l'engagement est disponible sur notre site internet :

- https://www.montpensier.com/sites/default/files/public/documents/engagement_rapport.pdf

2. Rapport sur l'exercice des droits de vote

Exercice 2023 AESCULAPE SRI

Ce document présente les conditions dans lesquelles les gérants OPC de Montpensier Finance ont exercé, au cours de l'année 2023, les droits de vote attachés aux titres détenus par le fonds AESCULAPE SRI dont elle assure la gestion.

2.1. Exercice des droits de vote

Le périmètre a porté sur 52 sociétés, qui ont été détenues dans AESCULAPE SRI, détenues dans les portefeuilles des OPC gérés par Montpensier Finance, au moment de leurs Assemblées Générales.

Vote effectif aux Assemblées Générales :

AG / Zones géographiques	Nombre total d'AG	Nombre d'AG votées	Pourcentage d'AG votées
France	9	9	100%
Hors France	48	47	98%
Total	57	56	98%

Le nombre total d'assemblées générales est obtenu à partir du nombre d'OPC convoqués à chacune des assemblées générales.


Les gérants n'ont pas voté à 2% des Assemblées Générales, pour des raisons techniques ou administratives.

Répartition des résolutions par zone géographique :

Résolutions / Zones géographiques	Total résolutions votées	Vote « pour »	Vote « contre »	« abstention »
France	214	141	73	0
Hors France	702	606	69	27
Total	916	747	142	27

Résolutions / Zone Géographique	Total résolutions votées	Vote « pour »	Vote « contre »	Vote « abstention »
France	214	141	73	--
Zone Euro hors France	126	107	19	--
Europe hors zone Euro	274	235	37	2
Amérique du Nord	247	214	8	25
Asie-Pacifique	19	19	--	--
Autres Zones	36	31	5	--
Total	916	747	142	27

Répartition des résolutions et des votes par zone géographique :



Répartition des Assemblées Générales par pays :

Résolutions / Pays	Nombre total d'AG	Nombre d'AG votées	Nombre d'AG non votées	Pourcentage d'AG votées
France	9	9	--	100%
Allemagne	3	3	--	100%
Autriche	--	--	--	--
Belgique	1	1	--	100%
Espagne	--	--	--	--
Finlande	--	--	--	--
Grèce	--	--	--	--
Irlande	2	2	--	100%
Italie	1	1	--	100%
Luxembourg	--	--	--	--
Pays-Bas	1	1	--	100%
Portugal	--	--	--	--
Danemark	4	4	--	100%
Norvège	--	--	--	--
Royaume-Uni	2	2	--	100%
Suède	2	2	--	100%
Suisse	5	5	--	100%
Autres Pays Européens	--	--	--	--
États-Unis	20	20	--	100%
Canada	--	--	--	--
Autres Pays non Européens	7	6	1	86%
Total	57	56	1	98%

Certains pays, dont la Suisse notamment, demandent un blocage des titres afin de permettre la participation aux Assemblées Générales, ce qui a pour conséquence de limiter l'accès aux votes. Afin de pouvoir participer aux votes en laissant au gérant la possibilité d'arbitrer le portefeuille, depuis le 2ème trimestre 2019, sauf autre contrainte technique, Montpensier Finance vote sur 75% de la position de chaque fonds détenue dans des valeurs nécessitant un blocage de la position.

Répartition des Votes aux Assemblées Générales par zones géographiques :

Résolutions / Pays	Total résolutions votées	Vote « pour »	Vote « contre »	Vote « abstention »
France	23%	15%	8%	--
Zone Euro hors France	14%	12%	2%	--
Europe hors zone Euro	30%	26%	4%	0.2%
Amérique du Nord	27%	23%	0.9%	3%
Asie-Pacifique	2%	2%	--	--
Autres Zones	4%	3%	0.5%	--
Total	100%	81.6%	15.5%	2.9%

La France représente 51% des votes d'oppositions et reste un des pays où le nombre de votes « contre » est le plus important.

Répartition des résolutions par typologie :

Résolutions / Typologie	Total résolutions votées	Vote « pour »	Vote « contre » ou « abstention »
Conseil d'administration, comité exécutif et autres	48%	41%	7%
Politique de rémunération et objectifs	19%	14%	6%
Structure actionnariale & contrôle	13%	9%	4%
Statuts	3%	3%	0.4%
Politique de distribution	3%	3%	--
Pratiques comptables et communication financière	11%	10%	0.7%
Environnement	--	--	--
Social	2%	2%	0.4%
E&S	--	--	--
Divers	0.5%	0.4%	0.1%
Opérations Stratégiques	--	--	--
Total	100%	81.6%	18.4%

Parmi les 916 résolutions votées, 878 étaient proposées par la direction ou le conseil d'administration ou de surveillance. Les gérants ont voté en opposition aux recommandations du management à 143 résolutions, soit 16.3%.

Sur les 38 résolutions proposées par les actionnaires, les gérants ont voté « pour » 25 résolutions, soit 65.8%.

Répartition par thématique des votes « contre » ou « abstention » :

Résolutions / Typologie	Vote « contre »	Vote « abstention »
Structure des Conseils et Auditeurs	29%	85%
Rémunérations	36%	11%
Statuts, Actionnariat et contrôle	28%	--
Distribution & Financier	4%	4%
Environnemental & Social	3%	--
Autres	0.7%	--
Total	100%	100%

Résolutions relatives aux Administrateurs et aux Auditeurs

La structure des conseils dépend du choix des administrateurs. Ce choix est primordial afin de garantir un conseil équilibré, responsable, engagé et efficace. Ainsi, pour cette thématique, nous exerçons nos droits de vote dans le but d'améliorer la différenciation des pouvoirs de direction et de surveillance, la constitution et le fonctionnement des comités spécialisés, et notamment des comités d'audit, ou encore la promotion d'administrateurs libres d'intérêts, dont la biographie est suffisamment détaillée, et qui sont suffisamment responsables et disponibles pour assurer leur fonction. En outre, nous sommes très attentifs aux modalités d'élection et à la responsabilité des administrateurs lors des défaillances de gouvernance.

Résolutions relatives aux Rémunérations

Nous considérons que la rémunération des dirigeants et des administrateurs doit être fonction du travail effectué et liée à l'évolution de la valeur intrinsèque de la société et de sa performance relative, financière comme extra-financière (selon des critères ESG par exemple), tout en s'inscrivant sur le long terme. Dans cette thématique, nous jugeons également l'existence et la cohérence de comités de rémunération, le « Say on Pay », la transparence des rémunérations, toutes formes de rémunérations indirectes ou encore la part et les incitations retenues dans la rémunération variable.

Résolutions relatives aux Statuts et aux Opérations sur capital

Pour cette thématique, nous veillons notamment sur les opérations d'augmentation de capital qui représenteraient un risque excessif de dilution et qui auraient donc un impact négatif pour les actionnaires, telles que les augmentations de capital sans droit préférentiel de souscription et sans délai de priorité, mais aussi sur les mesures anti-OPA, comme les rachats d'actions ou l'utilisation de « Poison Pills ».

Répartition des résolutions proposées par les actionnaires :

Résolutions / Typologie	Total résolutions votées	Vote « pour »	Vote « contre » ou « abstention »
Conseil d'administration, comité exécutif et autres	26%	13%	13%
Politique de rémunération et objectifs	8%	5%	3%
Structure actionnariale & contrôle	11%	8%	3%
Statuts	--	--	--
Politique de distribution	--	--	--
Pratiques comptables et communication financière	8%	5%	3%
Environnement	--	--	--
Social	45%	34%	11%
E&S	--	--	--
Divers	3%	--	3%
Opérations Stratégiques	--	--	--
Total	100%	66%	34%

Répartition par thématique des résolutions proposées par les actionnaires

Résolutions / Typologie	Vote « pour »	Vote « contre »	Vote « abstention »
Structure des Conseils et Auditeurs	20%	--	100%
Rémunérations	8%	13%	--
Statuts, Actionnariat et contrôle	12%	13%	--
Distribution & Financier	8%	13%	--
Environnemental & Social	52%	50%	--
Autres	--	13%	--
Total	100%	100%	100%

La majorité des résolutions proposées par les actionnaires portent sur des sujets financiers ou de gouvernance.

2.2. Les principes de la politique de vote

Conformément à la déontologie, les gérants exercent leurs fonctions en toute indépendance, notamment vis à vis des émetteurs, et dans l'intérêt exclusif des porteurs.

Au cours de l'exercice, les gérants n'ont pas indiqué avoir rencontré de cas dans lesquels ils ont estimé ne pas pouvoir respecter les principes fixés dans la « politique de vote ».

En 2023, les gérants ont voté différemment des recommandations émises par ISS Governance dans le cadre de sa politique Sustainability, à 16 résolutions, soit 1.7% des résolutions. Ces votes ont été justifiés.

Ces votes concernent essentiellement une appréciation plus qualitative par les gérants de Montpensier Finance de certaines candidatures d'administrateurs qui leur paraissent dans l'intérêt de la société et des actionnaires. Ils portent également sur la politique de rémunération des dirigeants.

Les gérants apprécient les résolutions dans le cadre de la politique de vote, au regard des spécificités des sociétés, de leur taille, de leur secteur d'activité et de leur pays d'incorporation.

2.3. Les conflits d'intérêts

Montpensier Finance a établi et maintient opérationnelle une politique de gestion des conflits d'intérêts.

Cette politique a pour objectif d'identifier les situations qui donnent ou sont susceptibles de donner lieu à un conflit d'intérêts comportant un risque sensible d'atteinte aux intérêts d'un ou de plusieurs clients, et de définir les procédures à suivre et les mesures à prendre en vue de gérer ces conflits.

Dans ce cadre, Montpensier Finance a réalisé une cartographie des situations de conflits d'intérêts potentiels, qui recense les situations susceptibles de générer des conflits d'intérêts eu égard à sa taille, à son organisation, à la nature, l'importance et la complexité de son activité, et définit les grandes lignes des procédures mises en œuvre par la société pour prévenir, encadrer, gérer ces conflits d'intérêts.

Les gérants n'ont pas signalé au RCCI de conflit d'intérêts potentiel durant l'année 2023.

2.4. Le mode d'exercice des droits de vote

Au cours de l'exercice, Montpensier Finance a exercé les droits de vote attachés aux actions détenues dans les portefeuilles des OPC gérés, par correspondance, via l'outil ProxyExchange d'ISS Governance, auquel Montpensier Finance a souscrit.

Les gérants n'ont pas signalé avoir eu recours au vote par procuration, ou pouvoirs au président.

3. Détail des votes aux résolutions présentées en Assemblée Générale

Exercice 2023 AESCULAPE SRI

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Allocation of Income and Dividends	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Ratify Auditors	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Elect Supervisory Board Member	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Remuneration of Directors and/or Committee Members	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Allow Shareholder Meetings to be Held in Virtual-Only Format	For	Against
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Amend Articles Board-Related	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Amend Articles Board-Related	For	For
DE000SHL1006	Siemens Healthineers AG	Allemagne	Aesculape SRI	Annual	15/02/2023	Approve Affiliation Agreements with Subsidiaries	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Accept Financial Statements and Statutory Reports	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Approve Discharge of Board and President (Bundled)	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Approve Allocation of Income and Dividends	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Approve Reduction in Share Capital	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Authorize Share Repurchase Program	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Amend Articles/Bylaws/Charter -- Non-Routine	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Adopt New Articles of Association/Charter	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Adopt New Articles of Association/Charter	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Approve Remuneration of Directors and/or Committee Members	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	Against
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Director	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Member of Remuneration Committee	For	Against
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Member of Remuneration Committee	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Member of Remuneration Committee	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Elect Member of Remuneration Committee	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Ratify Auditors	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Designate X as Independent Proxy	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Annual	07/03/2023	Other Business	For	Against
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Approve Allocation of Income and Dividends	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Approve Discharge of Management Board (Bundled)	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Approve Discharge of Supervisory Board (Bundled)	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Ratify Auditors	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Allow Shareholder Meetings to be Held in Virtual-Only Format	For	Against
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Amend Articles Board-Related	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	Against
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	Against
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Elect Supervisory Board Member	For	For
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Approve Remuneration Policy	For	Against
DE0005313704	Carl Zeiss Meditec AG	Allemagne	Aesculape SRI	Annual	22/03/2023	Company-Specific--Compensation-Related	For	Against
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Accept Financial Statements and Statutory Reports	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Allocation of Income and Dividends	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Remuneration of Directors and/or Committee Members	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Remuneration of Directors and/or Committee Members	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Remuneration Policy	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Board Chairman/Vice-Chairman	For	Abstain
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Board Chairman/Vice-Chairman	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Elect Director	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Ratify Auditors	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Reduction in Share Capital	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Authorize Share Repurchase Program	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Company-Specific -- Shareholder Miscellaneous	Against	Against
DK0060534915	Novo Nordisk A/S	Danemark	Aesculape SRI	Annual	23/03/2023	Transact Other Business (Non-Voting)		
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Financial Statements, Allocation of Income, and Discharge Directors	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Allocation of Income and Dividends	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Remuneration Policy	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Remuneration-Related	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Remuneration Policy	For	Against
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Remuneration Policy	For	Against
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Authorize Share Repurchase Program	For	Against
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Authorize Filing of Required Documents/Other Formalities	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Issuance of Shares for a Private Placement	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Reduction in Share Capital	For	For
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Approve Qualified Employee Stock Purchase Plan	Against	Against
FR0013154002	Sartorius Stedim Biotech SA	France	Aesculape SRI	Annual/Special	27/03/2023	Authorize Filing of Required Documents/Other Formalities	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Approve Financial Statements, Allocation of Income, and Discharge Directors	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Approve Allocation of Income and Dividends	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Ratify Auditors	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Approve Remuneration of Directors and/or Committee Members	For	Against
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Approve Remuneration Policy	For	Against
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Approve Remuneration Policy	For	Against
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Authorize Share Repurchase Program	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Authorize Filing of Required Documents/Other Formalities	For	For
DK0010272202	Genmab A/S	Danemark	Aesculape SRI	Annual	29/03/2023	Transact Other Business (Non-Voting)		
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Elect Director	For	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Elect Director	For	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Elect Director	For	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Provide Right to Call Special Meeting	For	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Amend Articles/Bylaws/Charter - Call Special Meetings	Against	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Require Independent Board Chairman	Against	For
US46266C1053	IQVIA Holdings Inc.	États-Unis	Aesculape SRI	Annual	18/04/2023	Ratify Auditors	For	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Accept Financial Statements and Statutory Reports	For	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Approve Allocation of Income and Dividends	For	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Appoint Alternate Internal Statutory Auditor(s) [and Approve Auditor's/Auditors' Remuneration]	None	Against
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Appoint Alternate Internal Statutory Auditor(s) [and Approve Auditor's/Auditors' Remuneration]	None	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Appoint Chairman of Internal Statutory Auditor(s) [and Approve His/Her Remuneration]	None	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Company-Specific Board-Related	None	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Approve Remuneration Policy	For	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Approve Restricted Stock Plan	For	Against
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Authorize Share Repurchase Program and Reissuance of Repurchased Shares	For	For
IT0003828271	Recordati SpA	Italie	Aesculape SRI	Annual	21/04/2023	Deliberations on Possible Legal Action Against Directors/(Internal) Auditors	None	Against
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Ratify Auditors	For	For
US46120E6023	Intuitive Surgical, Inc.	États-Unis	Aesculape SRI	Annual	27/04/2023	Gender Pay Gap	Against	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Ratify Auditors	For	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Amend Articles/Bylaws/Charter -- Non-Routine		
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Review Drug Pricing or Distribution	Against	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Use GAAP for Executive Compensation Metrics	Against	For
US4781601046	Johnson & Johnson	États-Unis	Aesculape SRI	Annual	27/04/2023	Review Drug Pricing or Distribution	Against	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Accept Financial Statements and Statutory Reports	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Allocation of Income and Dividends	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Dividends	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Discharge of Board and President (Bundled)	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Director	For	Against
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Director	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Board Chairman/Vice-Chairman	For	Against
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Member of Remuneration Committee	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Elect Member of Remuneration Committee	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Designate X as Independent Proxy	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Ratify Auditors	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Remuneration of Directors and/or Committee Members	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Remuneration of Directors and/or Committee Members	For	Against
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Amend Articles/Bylaws/Charter -- Non-Routine	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Adopt New Articles of Association/Charter	For	Against
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Adopt New Articles of Association/Charter	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Amend Articles/Charter Compensation-Related	For	For
CH0468525222	Medacta Group SA	Suisse	Aesculape SRI	Annual	27/04/2023	Other Business	For	Against
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Receive Consolidated Financial Statements and Statutory Reports (Non-Voting)		
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Financial Statements, Allocation of Income, and Discharge Directors	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Discharge of Board and President (Bundled)	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Discharge of Auditors	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Elect Director	For	Against
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Indicate X as Independent Board Member	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Elect Director	For	Against
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Elect Director	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Indicate X as Independent Board Member	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Restricted Stock Plan	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Change-of-Control Clause	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Change-of-Control Clause	For	For
BE0003739530	UCB SA	Belgique	Aesculape SRI	Annual/Special	27/04/2023	Approve Change-of-Control Clause	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Elect Director	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Elect Director	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Elect Director	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Elect Director	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Ratify Auditors	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Declassify the Board of Directors	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Reduce Supermajority Vote Requirement	For	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Political Lobbying Disclosure	Against	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Amend Vote Requirements to Amend Articles/Bylaws/Charter	Against	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Review Drug Pricing or Distribution	Against	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Avoid Support of Abortion-Related Activities	Against	Against
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Political Spending Congruency	Against	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Report on EEO	Against	For
US5324571083	Eli Lilly and Company	États-Unis	Aesculape SRI	Annual	01/05/2023	Political Contributions Disclosure	Against	Against
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Elect Director	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Ratify Auditors	For	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Require Independent Board Chairman	Against	For
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Miscellaneous -- Environmental & Social Counterproposal	Against	Against
US1101221083	Bristol-Myers Squibb Company	États-Unis	Aesculape SRI	Annual	02/05/2023	Amend Articles/Bylaws/Charter - Call Special Meetings	Against	Against
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Accept Financial Statements and Statutory Reports	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Ratify Auditors	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Authorize Board to Fix Remuneration of External Auditor(s)	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Approve Remuneration Policy	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Approve Political Donations	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Authorize Share Repurchase Program	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Miscellaneous Proposal: Company-Specific	For	For
GB00BN7SWP63	GSK Plc	Royaume-Uni	Aesculape SRI	Annual	03/05/2023	Authorize the Company to Call EGM with Two Weeks Notice	For	For
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Elect Director	For	For
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Elect Director	For	Withhold
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Ratify Auditors	For	For
US60770K1079	Moderna, Inc.	États-Unis	Aesculape SRI	Annual	03/05/2023	Review Drug Pricing or Distribution	Against	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Elect Director	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US1011371077	Boston Scientific Corporation	États-Unis	Aesculape SRI	Annual	04/05/2023	Ratify Auditors	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Ratify Auditors	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Reduce Supermajority Vote Requirement	For	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Reduce Supermajority Vote Requirement	Against	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Political Spending Congruency	Against	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Political Lobbying Disclosure	Against	For
US00287Y1091	AbbVie Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Review Drug Pricing or Distribution	Against	For
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US40637H1095	Halozyyme Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	05/05/2023	Ratify Auditors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Accept Financial Statements and Statutory Reports	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Discharge of Board and President (Bundled)	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Allocation of Income and Dividends	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	Against
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Director	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Board Chairman/Vice-Chairman	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Member of Remuneration Committee	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Member of Remuneration Committee	For	Against
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Elect Member of Remuneration Committee	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Ratify Auditors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Ratify Auditors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Designate X as Independent Proxy	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Amend Corporate Purpose	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Amend Articles/Charter Compensation-Related	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Adopt New Articles of Association/Charter	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Remuneration of Directors and/or Committee Members	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	For
CH0013841017	Lonza Group AG	Suisse	Aesculape SRI	Annual	05/05/2023	Other Business	For	Against
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Open Meeting		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Chairman of Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Prepare and Approve List of Shareholders	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Minutes of Previous Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Designate Inspector or Shareholder Representative(s) of Minutes of Meeting and/or Vote Tabulation		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Acknowledge Proper Convening of Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Receive/Approve Report/Announcement		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Accept Financial Statements and Statutory Reports	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Allocation of Income and Dividends	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Supervisory Board Member XXX/Non-Executive Board Member XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Discharge of Management Board Member XXX/Executive Director XXX (INDIVIDUAL RESOLUTION)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Remuneration of Directors and/or Committee Members	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Authorize Board to Fix Remuneration of External Auditor(s)	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Fix Number of Directors and/or Auditors	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Fix Number of Directors and/or Auditors	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Director	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Elect Board Chairman/Vice-Chairman	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Ratify Auditors	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Restricted Stock Plan	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Restricted Stock Plan	For	Against
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Equity Plan Financing	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Equity Plan Financing	For	Against
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Alternative Equity Plan Financing	For	Against
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Approve Equity Plan Financing	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Annual	09/05/2023	Close Meeting		
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Elect Director	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Ratify Auditors	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Issue Updated Indemnification, Liability and Exculpation Agreements for Directors	For	For
US28176E1082	Edwards Lifesciences Corporation	États-Unis	Aesculape SRI	Annual	11/05/2023	Require Independent Board Chairman	Against	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Elect Director	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Ratify Auditors	For	For
US2290503075	CryoPort, Inc.	États-Unis	Aesculape SRI	Annual	12/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Elect Director	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Elect Director	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Elect Director	For	Against
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Elect Director	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Ratify Auditors	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
IE00B91XRN20	Prothena Corporation plc	Irlande	Aesculape SRI	Annual	16/05/2023	Amend Omnibus Stock Plan	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Amend Omnibus Stock Plan	For	For
US64125C1099	Neurocrine Biosciences, Inc.	États-Unis	Aesculape SRI	Annual	17/05/2023	Ratify Auditors	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Elect Director	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Ratify Auditors	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US92532F1003	Vertex Pharmaceuticals Incorporated	États-Unis	Aesculape SRI	Annual	17/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US56600D1072	Maravai LifeSciences Holdings, Inc.	États-Unis	Aesculape SRI	Annual	18/05/2023	Elect Director	For	Withhold
US56600D1072	Maravai LifeSciences Holdings, Inc.	États-Unis	Aesculape SRI	Annual	18/05/2023	Elect Director	For	Withhold
US56600D1072	Maravai LifeSciences Holdings, Inc.	États-Unis	Aesculape SRI	Annual	18/05/2023	Elect Director	For	Withhold
US56600D1072	Maravai LifeSciences Holdings, Inc.	États-Unis	Aesculape SRI	Annual	18/05/2023	Ratify Auditors	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Elect Director	For	For
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Ratify Auditors	For	For
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Amend Omnibus Stock Plan	For	For
US8835561023	Thermo Fisher Scientific Inc.	États-Unis	Aesculape SRI	Annual	24/05/2023	Approve Qualified Employee Stock Purchase Plan	For	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	Against	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	Against	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	Against	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Ratify Auditors	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Advisory Vote on Say on Pay Frequency	One Year	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Amend Omnibus Stock Plan	For	Do Not Vote
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	For	Withhold
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	For	Withhold
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Dissident)	For	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	None	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	Against	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Elect Director (Management)	Against	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Ratify Auditors	For	For
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	Against	Against
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US4523271090	Illumina, Inc.	États-Unis	Aesculape SRI	Proxy Contest	25/05/2023	Amend Omnibus Stock Plan	None	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Accept Financial Statements and Statutory Reports	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Allocation of Income and Dividends	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Elect Director	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Remuneration-Related	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Remuneration of Directors and/or Committee Members	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Remuneration Policy	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Remuneration Policy	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Ratify Auditors	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Change Location of Registered Office/Headquarters	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Share Repurchase Program	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Reduction in Share Capital	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Issuance of Shares for a Private Placement	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Issuance of Securities Convertible into Debt	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Capital Increase of up to 10 Percent of Issued Capital for Future Acquisitions	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Capitalization of Reserves for Bonus Issue or Increase in Par Value	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Approve Qualified Employee Stock Purchase Plan	For	For
FR0000120578	Sanofi	France	Aesculape SRI	Annual/Special	25/05/2023	Authorize Filing of Required Documents/Other Formalities	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Accept Financial Statements and Statutory Reports	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Allocation of Income and Dividends	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Elect Director	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Remuneration-Related	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Remuneration Policy	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Remuneration Policy	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Remuneration Policy	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Share Repurchase Program	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Reduction in Share Capital	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Board to Set Issue Price for 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Capitalization of Reserves for Bonus Issue or Increase in Par Value	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Capital Increase of up to 10 Percent of Issued Capital for Future Acquisitions	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Capital Increase for Future Share Exchange Offers	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Set Global Limit for Capital Increase to Result From All Issuance Requests	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Executive Share Option Plan	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve/Amend Issuance of Warrants Reserved for Founders	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Restricted Stock Plan	For	Against
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Company-Specific Compensation-Related	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Approve Qualified Employee Stock Purchase Plan	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Ratify Auditors	For	For
FR0012333284	Abivax SA	France	Aesculape SRI	Annual/Special	05/06/2023	Authorize Filing of Required Documents/Other Formalities	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Elect Director	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Ratify Auditors	For	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Racial Equity and/or Civil Rights Audit	Against	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Political Spending Congruency	Against	For
US91324P1021	UnitedHealth Group Incorporated	États-Unis	Aesculape SRI	Annual	05/06/2023	Submit Severance Agreement to Shareholder Vote	Against	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Approve Allocation of Income and Dividends	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Approve Discharge of Management Board (Bundled)	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Approve Discharge of Supervisory Board (Bundled)	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Ratify Auditors	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Allow Shareholder Meetings to be Held in Virtual-Only Format	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
DE000A0LD6E6	Gerresheimer AG	Allemagne	Aesculape SRI	Annual	07/06/2023	Authorize Issuance of Warrants/Bonds with Warrants Attached/Convertible Bonds without Preemptive Rights	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Treatment of Net Loss	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Discharge of Management Board (Bundled)	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Director	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Member of Remuneration Committee	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Member of Remuneration Committee	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Member of Remuneration Committee	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Elect Member of Remuneration Committee	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Remuneration of Directors and/or Committee Members	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Remuneration of Directors and/or Committee Members	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Remuneration of Executive Directors and/or Non-Executive Directors	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Company Specific - Equity Related	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Qualified Employee Stock Purchase Plan	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Amend Omnibus Stock Plan	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Approve Decrease in Size of Board	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Amend Corporate Purpose	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Amend Articles/Bylaws/Charter -- Non-Routine	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Amend Articles/Bylaws/Charter -- Non-Routine	For	Against
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Adopt New Articles of Association/Charter	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Adopt New Articles of Association/Charter	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Designate X as Independent Proxy	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Ratify Auditors	For	For
CH0334081137	CRISPR Therapeutics AG	Suisse	Aesculape SRI	Annual	08/06/2023	Other Business	For	Against
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Elect Director	For	Against
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Elect Director	For	Against
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Elect Director	For	For
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Elect Director	For	For
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Ratify Auditors	For	For
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Advisory Vote on Say on Pay Frequency	One Year	One Year
US75886F1075	Regeneron Pharmaceuticals, Inc.	États-Unis	Aesculape SRI	Annual	09/06/2023	Review Drug Pricing or Distribution	Against	Against
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Approve Allocation of Income and Dividends	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Elect Director	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Appoint Internal Statutory Auditor(s) [and Approve Auditor's/Auditors' Remuneration]	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Appoint Internal Statutory Auditor(s) [and Approve Auditor's/Auditors' Remuneration]	For	For
JP3475350009	Daiichi Sankyo Co., Ltd.	Japon	Aesculape SRI	Annual	19/06/2023	Approve Restricted Stock Plan	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Accept Financial Statements and Statutory Reports	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Allocation of Income and Dividends	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Discharge of Board and President (Bundled)	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Elect Director	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Elect Director	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Elect Director	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Elect Director	For	Against

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Remuneration of Directors and/or Committee Members	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Authorize Share Repurchase Program	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Reduction in Share Capital	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Set Global Limit for Capital Increase to Result From All Issuance Requests	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Qualified Employee Stock Purchase Plan	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Cancellation of Capital Authorization	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Approve Issuance of Shares for a Private Placement	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Eliminate Preemptive Rights	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Consider Measures to Address the Decline in the Company's Net Asset Value Relative to Its Capital	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Annual/Special	20/06/2023	Authorize Filing of Required Documents/Other Formalities	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Accept Financial Statements and Statutory Reports	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Allocation of Income and Dividends	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Elect Supervisory Board Member	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Elect Supervisory Board Member	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Elect Supervisory Board Member	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Ratify Auditors	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Remuneration Policy	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Remuneration Policy	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Remuneration-Related	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Share Repurchase Program	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Amend Articles Board-Related	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Reduction in Share Capital	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Board to Set Issue Price for 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Capitalization of Reserves for Bonus Issue or Increase in Par Value	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Capital Increase of up to 10 Percent of Issued Capital for Future Acquisitions	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Set Global Limit for Capital Increase to Result From All Issuance Requests	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Executive Share Option Plan	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Restricted Stock Plan	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Approve Qualified Employee Stock Purchase Plan	Against	For
FR0004056851	Valneva SE	France	Aesculape SRI	Annual/Special	21/06/2023	Authorize Filing of Required Documents/Other Formalities	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Accept Financial Statements and Statutory Reports	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Discharge of Management Board (Bundled)	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Discharge of Supervisory Board (Bundled)	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Elect Supervisory Board Member	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Executive Appointment	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Executive Appointment	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Ratify Auditors	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Eliminate Preemptive Rights	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Authorize Share Repurchase Program	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Company Specific - Equity Related	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Reduction in Share Capital	For	For
NL0012169213	QIAGEN NV	Pays-Bas	Aesculape SRI	Annual	22/06/2023	Approve Executive Share Option Plan	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	Against
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	Against
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	Against
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	Against
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Elect Director	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Ratify Auditors	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Accept Financial Statements and Statutory Reports	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Ratify Auditors	For	For
GB00BMVP7Y09	Royalty Pharma Plc	Royaume-Uni	Aesculape SRI	Annual	22/06/2023	Authorize Board to Fix Remuneration of External Auditor(s)	For	For
US00973Y1082	Akero Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	23/06/2023	Elect Director	For	For
US00973Y1082	Akero Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	23/06/2023	Elect Director	For	Withhold
US00973Y1082	Akero Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	23/06/2023	Elect Director	For	Withhold
US00973Y1082	Akero Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	23/06/2023	Ratify Auditors	For	For
US00973Y1082	Akero Therapeutics, Inc.	États-Unis	Aesculape SRI	Annual	23/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Accept Financial Statements and Statutory Reports	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Elect Director	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Elect Director	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Elect Director	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Approve Remuneration of Directors and/or Committee Members	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Approve Auditors and Authorize Board to Fix Their Remuneration	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Authorize Share Repurchase Program	For	For
KYG0146B1032	Akeso, Inc.	Caïmanes, îles	Aesculape SRI	Annual	28/06/2023	Authorize Reissuance of Repurchased Shares	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Accept Financial Statements and Statutory Reports	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Discharge of Directors and Auditors (Bundled)	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Allocation of Income and Dividends	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Elect Director	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Elect Director	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Elect Director	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Ratify Auditors	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Remuneration-Related	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Remuneration Policy	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Remuneration Policy	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Remuneration Policy	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Remuneration Policy	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Approve Remuneration of Directors and/or Committee Members	For	For
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Authorize Share Repurchase Program	For	Against
FR0012882389	Equasens	France	Aesculape SRI	Annual	29/06/2023	Authorize Filing of Required Documents/Other Formalities	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Elect Director	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Accept Financial Statements and Statutory Reports	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Authorize Board to Fix Remuneration of External Auditor(s)	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Authorize Share Repurchase Program	For	For
IE0005711209	ICON plc	Irlande	Aesculape SRI	Annual	25/07/2023	Authorize Reissuance of Repurchased Shares	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Open Meeting		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Elect Chairman of Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Prepare and Approve List of Shareholders	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Approve Minutes of Previous Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Designate Inspector or Shareholder Representative(s) of Minutes of Meeting and/or Vote Tabulation		
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Acknowledge Proper Convening of Meeting	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Approve Equity Plan Financing	For	For
SE0000872095	Swedish Orphan Biovitrum AB	Suède	Aesculape SRI	Extraordinary Shareholders	15/08/2023	Close Meeting		
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Accept Financial Statements and Statutory Reports	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Accept Consolidated Financial Statements and Statutory Reports	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Allocation of Income and Dividends	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Consider Measures to Address the Decline in the Company's Net Asset Value Relative to Its Capital	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Special Auditors' Report Regarding Related-Party Transactions	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Elect Supervisory Board Member	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Elect Supervisory Board Member	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Elect Supervisory Board Member	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Elect Supervisory Board Member	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Remuneration-Related	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Remuneration Policy	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Remuneration Policy	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Remuneration Policy	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Remuneration Policy	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Remuneration Policy	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Share Repurchase Program	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Reduction in Share Capital	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Issuance of Shares for a Private Placement	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Board to Set Issue Price for 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Capitalization of Reserves for Bonus Issue or Increase in Par Value	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Capital Increase of up to 10 Percent of Issued Capital for Future Acquisitions	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Capital Increase for Future Share Exchange Offers	For	Against

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Set Global Limit for Capital Increase to Result From All Issuance Requests	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Executive Share Option Plan	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve/Amend Issuance of Warrants Reserved for Founders	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Restricted Stock Plan	For	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Company-Specific Compensation-Related	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Approve Qualified Employee Stock Purchase Plan	Against	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Company Specific - Equity Related	For	For
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Consider Measures to Address the Decline in the Company's Net Asset Value Relative to Its Capital	Against	Against
FR0004065605	MedinCell SA	France	Aesculape SRI	Annual/Special	12/09/2023	Authorize Filing of Required Documents/Other Formalities	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Extraordinary Shareholders	15/09/2023	Approve Spin-Off Agreement	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Extraordinary Shareholders	15/09/2023	Approve Reduction in Share Capital	For	For
CH0012005267	Novartis AG	Suisse	Aesculape SRI	Extraordinary Shareholders	15/09/2023	Other Business	For	Against
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Accept Financial Statements and Statutory Reports	For	For
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Ratify Auditors	For	For
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Elect Director	For	For
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Elect Director	For	For
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Elect Director	For	For
US52490G1022	Legend Biotech Corporation	Caïmanes, îles	Aesculape SRI	Annual	21/09/2023	Authorize Board to Ratify and Execute Approved Resolutions	For	For
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Change Jurisdiction of Incorporation []	For	For
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Company Specific - Equity Related	For	For
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Eliminate Cumulative Voting	For	Against
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Issue Updated Indemnification, Liability and Exculpation Agreements for Directors	For	For
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Adopt the Jurisdiction of Incorporation as the Exclusive Forum for Certain Disputes	For	For
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Classify the Board of Directors	For	Against
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Adopt or Increase Supermajority Vote Requirement for Amendments	For	Against
US02290A1025	Ambrx Biopharma, Inc.	Caïmanes, îles	Aesculape SRI	Extraordinary Shareholders	10/10/2023	Adjourn Meeting	For	For
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Ordinary Shareholders	10/10/2023	Elect Director	For	Against
FR0011049824	MEDIAN Technologies SA	France	Aesculape SRI	Ordinary Shareholders	10/10/2023	Authorize Filing of Required Documents/Other Formalities	For	For
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Accept Financial Statements and Statutory Reports	For	For
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Elect Director	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Elect Director	For	For
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Approve Share Plan Grant	For	For
AU000000COH5	Cochlear Limited	Australie	Aesculape SRI	Annual	17/10/2023	Renew Partial Takeover Provision	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Accept Financial Statements and Statutory Reports	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Approve Allocation of Income and Dividends	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Approve Remuneration of Directors and/or Committee Members	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Issue Updated Indemnification, Liability and Exculpation Agreements for Directors	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Amend Articles Board-Related	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Approve Remuneration Policy	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Authorize Share Repurchase Program	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Elect Director	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Ratify Auditors	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Authorize Filing of Required Documents/Other Formalities	For	For
DK0060448595	Coloplast A/S	Danemark	Aesculape SRI	Annual	07/12/2023	Transact Other Business (Non-Voting)		
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Receive Financial Statements and Statutory Reports (Non-Voting)		
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Accept Financial Statements and Statutory Reports	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Advisory Vote to Ratify Named Executive Officers' Compensation	For	Against
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Approve Allocation of Income and Dividends	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Approve Remuneration of Directors and/or Committee Members	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	Abstain
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Elect Director	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Ratify Auditors	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Issue Updated Indemnification, Liability and Exculpation Agreements for Directors	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Amend Articles Board-Related	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Approve Remuneration Policy	For	For
DK0060946788	Ambu A/S	Danemark	Aesculape SRI	Annual	13/12/2023	Authorize Filing of Required Documents/Other Formalities	For	For

ISIN	Valeur	Pays	Fonds	AG	Date AG	Résolution	Recommandation Management	Vote Société de Gestion
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Elect Director	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Remuneration Policy	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Remuneration Policy	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Remuneration of Directors and/or Committee Members	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Share Repurchase Program	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Company Specific--Board-Related	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Reduction in Share Capital	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Issuance of Shares for a Private Placement	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Board to Set Issue Price for 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Issuance of Shares for a Private Placement	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Board to Increase Capital in the Event of Demand Exceeding Amounts Submitted to Shareholder Vote Above	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Capitalization of Reserves for Bonus Issue or Increase in Par Value	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Capital Increase of up to 10 Percent of Issued Capital for Future Acquisitions	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Set Global Limit for Capital Increase to Result From All Issuance Requests	For	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Executive Share Option Plan	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Restricted Stock Plan	For	Against
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Approve Qualified Employee Stock Purchase Plan	Against	For
FR0004056851	Valneva SE	France	Aesculape SRI	Extraordinary Shareholders	20/12/2023	Authorize Filing of Required Documents/Other Formalities	For	For

Avertissement

Document non contractuel. Il est recommandé au donneur d'ordre, préalablement à toute prise de décision d'investissement ou de désinvestissement, de prendre connaissance des conditions de fonctionnement et des mécanismes régissant les marchés financiers, d'évaluer les risques y afférents et de recourir à tous moyens nécessaires à la bonne compréhension de ces mécanismes.

Dans ses choix d'investissement, l'investisseur doit toujours rester conscient du fait que certains actifs présentent des risques importants. LES CHIFFRES CITES ONT TRAIT AUX ANNEES ECOULEES. LES PERFORMANCES PASSEES NE SONT PAS UN INDICATEUR FIABLE DES PERFORMANCES FUTURES. Elles ne constituent en aucun cas une garantie future de performance ou de capital, qui peut ne pas être restitué intégralement. Les opinions émises dans le présent document peuvent être modifiées sans préavis. Le présent document ne constitue ni une offre d'achat, ni une proposition de vente, ni un conseil en investissement. Les valeurs citées sont susceptibles de ne pas/plus figurer dans les portefeuilles des OPC gérés par Montpensier Finance, et ne constituent en aucun cas une recommandation d'investissement ou de désinvestissement. La décision d'investir tient compte de toutes les caractéristiques, objectifs et risques de l'OPCVM. Il est recommandé, avant tout investissement, de LIRE ATTENTIVEMENT LE KID, LE PROSPECTUS et le DOCUMENT PRÉCONTRACTUEL SFDR DE L'OPCVM SOUSCRIT.

Montpensier Finance recommande à l'investisseur de consacrer le temps nécessaire à déterminer l'adéquation de l'investissement à son patrimoine et à définir la répartition diversifiée de ses avoirs conformément à ses objectifs, à ses contraintes, y compris règlementaires, et à son horizon de placement.

Plus cet horizon est court, moins il convient de prendre des risques. Il convient également qu'il vérifie l'horizon de placement de l'OPCVM et la catégorie d'investissement spécifiés dans le prospectus.

Les informations figurant dans le présent document, obtenues auprès de sources qui peuvent être considérées comme fiables, n'ont pas fait l'objet de vérifications et ne sauraient engager la responsabilité de Montpensier Finance. Montpensier Finance est susceptible de détenir des liens d'intérêt (notamment promoteur, gestionnaire ou distributeur) ou de détenir des positions sur les OPCVM ou les valeurs éventuellement mentionnés. Ce document est la propriété intellectuelle de Montpensier Finance. Le prospectus de l'OPCVM, le PCD et le KID sont disponibles chez Montpensier Finance et sur www.montpensier.com.

Les valeurs éventuellement citées dans le présent document sont susceptibles de ne plus figurer dans les portefeuilles des OPCVM gérés par Montpensier Finance, et ne constituent en aucun cas une recommandation d'investissement ou de désinvestissement.